• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review.肿瘤生物学是否决定了上皮性卵巢癌治疗的手术成功?系统文献回顾。
Br J Cancer. 2012 Sep 25;107(7):1069-74. doi: 10.1038/bjc.2012.376. Epub 2012 Aug 30.
2
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
3
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
5
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.超根治性(广泛)手术与标准手术治疗晚期上皮性卵巢癌的初步细胞减灭术。
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
6
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.术中冰冻切片分析用于诊断可疑盆腔肿块中的早期卵巢癌。
Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2.
7
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
A systematic overview of chemotherapy effects in ovarian cancer.卵巢癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

引用本文的文献

1
Characteristics of Oxidative Phosphorylation-Related Subtypes and Construction of a Prognostic Signature in Ovarian Cancer.卵巢癌中氧化磷酸化相关亚型的特征及预后标志物的构建
Curr Gene Ther. 2025;25(3):327-344. doi: 10.2174/0115665232323373240905104033.
2
New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.高级别浆液性卵巢癌患者治疗反应的新型免疫表型。
Front Immunol. 2024 Jun 14;15:1394497. doi: 10.3389/fimmu.2024.1394497. eCollection 2024.
3
Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease.对接受初次肿瘤细胞减灭术的卵巢癌患者进行全基因组关联分析,以确定残留疾病的候选基因。
NPJ Genom Med. 2024 Mar 5;9(1):19. doi: 10.1038/s41525-024-00395-y.
4
Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins.通过血清代谢物和脂蛋白变化评估高级别浆液性卵巢癌的主要治疗效果
Metabolites. 2023 Mar 12;13(3):417. doi: 10.3390/metabo13030417.
5
Search for New Participants in the Pathogenesis of High-Grade Serous Ovarian Cancer with the Potential to Be Used as Diagnostic Molecules.寻找高级别浆液性卵巢癌发病机制中的新参与者,其有潜力用作诊断分子。
Life (Basel). 2022 Dec 3;12(12):2017. doi: 10.3390/life12122017.
6
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
7
The gene predicts prognosis and response to chemotherapy in epithelial ovarian cancer.该基因可预测上皮性卵巢癌的预后及对化疗的反应。
Ann Transl Med. 2021 May;9(9):806. doi: 10.21037/atm-21-2087.
8
Promoter Methylation of the Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients.基因的启动子甲基化可预测高级别浆液性卵巢癌患者的预后及对化疗的反应。
Front Oncol. 2021 Jun 29;11:659254. doi: 10.3389/fonc.2021.659254. eCollection 2021.
9
PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma.PRMT1表达可预测卵巢浆液性癌患者对铂类化疗的敏感性。
Oncol Lett. 2021 Feb;21(2):162. doi: 10.3892/ol.2020.12423. Epub 2020 Dec 31.
10
The P72R Polymorphism in R248Q/W p53 Mutants Modifies the Mutant Effect on Epithelial to Mesenchymal Transition Phenotype and Cell Invasion via CXCL1 Expression.R248Q/W p53 突变体中的 P72R 多态性通过 CXCL1 表达改变突变体对上皮间质转化表型和细胞侵袭的影响。
Int J Mol Sci. 2020 Oct 28;21(21):8025. doi: 10.3390/ijms21218025.

本文引用的文献

1
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.p130cas 在卵巢癌中的沉默:肿瘤细胞死亡的新机制。
J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.
2
Rethinking ovarian cancer: recommendations for improving outcomes.重新思考卵巢癌:改善预后的建议。
Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.
3
Integrated genomic analyses of ovarian carcinoma.卵巢癌的综合基因组分析。
Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.
4
AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.AEG-1 过表达:上皮性卵巢癌腹膜播散和淋巴结转移的新指标。
Int J Gynecol Cancer. 2011 May;21(4):602-8. doi: 10.1097/IGC.0b013e3182145561.
5
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.对上皮性卵巢癌中 wnt 通路基因的系统性 CpG 岛甲基化谱分析确定了无进展生存期的生物标志物。
Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.
6
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.基因组分析揭示了卵巢透明细胞癌的分子异质性。
Clin Cancer Res. 2011 Mar 15;17(6):1521-34. doi: 10.1158/1078-0432.CCR-10-1688.
7
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.TGFß1 及其受体的表达与卵巢癌的生物学特征及对紫杉醇/卡铂的敏感性相关。
Oncol Rep. 2011 Apr;25(4):1131-8. doi: 10.3892/or.2011.1151. Epub 2011 Jan 18.
8
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.澳大利亚、加拿大、丹麦、挪威、瑞典和英国的癌症生存状况,1995-2007 年(国际癌症基准合作):基于人群的癌症登记数据分析。
Lancet. 2011 Jan 8;377(9760):127-38. doi: 10.1016/S0140-6736(10)62231-3. Epub 2010 Dec 21.
9
The genesis and evolution of high-grade serous ovarian cancer.高级别浆液性卵巢癌的发生和演进。
Nat Rev Cancer. 2010 Nov;10(11):803-8. doi: 10.1038/nrc2946. Epub 2010 Oct 14.
10
Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients.晚期原发性上皮性卵巢癌能否实现肿瘤完全切除?360 例连续患者的系统评价。
Eur J Surg Oncol. 2010 Dec;36(12):1202-10. doi: 10.1016/j.ejso.2010.09.008. Epub 2010 Sep 22.

肿瘤生物学是否决定了上皮性卵巢癌治疗的手术成功?系统文献回顾。

Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review.

机构信息

Epigenetics Unit, Department of Surgery and Cancer, Imperial College London, 4th Floor IRDB, Hammersmith Hospital, London W12 0NN, UK.

出版信息

Br J Cancer. 2012 Sep 25;107(7):1069-74. doi: 10.1038/bjc.2012.376. Epub 2012 Aug 30.

DOI:10.1038/bjc.2012.376
PMID:22935582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3461167/
Abstract

BACKGROUND

Ovarian cancer is the most lethal gynaecological cancer. Progression-free and overall survival is significantly related to surgical success and residual disease volume. It is unclear whether this survival advantage is due to an intrinsic biological element of the tumour cells which enables successful surgery and improved prognosis, or alternatively the number of tumour sustaining cells remaining irrespective of differences in biology.

METHODS

A systematic review of the literature was performed identifying studies that have investigated the association between biomarkers and surgical outcomes. We attempted validation of these results using The Cancer Genome Atlas ovarian cancer data sets.

RESULTS

Thirty studies were identified of which sixteen determined protein expression, eight gene expression and one DNA methylation in association with surgical debulking. Individualised linear models adjusting for batch, stage and age identified only expression of the genes MTDH and insulin-like growth factor-1 receptor (IGF1R) to be significantly associated with debulking surgery (P<0.05, false discovery rate (FDR)<5%), although in the case of IGF1R this was in the opposite direction to previous findings.

CONCLUSION

The majority of studies are limited by design, include heterogeneous samples and lack adjustment for major confounding factors. High quality detailed clinical annotations should be routinely collected in future to more accurately evaluate biomarkers of surgical outcome.

摘要

背景

卵巢癌是最致命的妇科癌症。无进展生存期和总生存期与手术成功和残留疾病体积显著相关。目前尚不清楚这种生存优势是由于肿瘤细胞的固有生物学特性使其能够成功手术和改善预后,还是由于肿瘤维持细胞的数量不受生物学差异的影响而导致的。

方法

对文献进行系统回顾,确定了研究生物标志物与手术结果之间关联的研究。我们试图使用癌症基因组图谱卵巢癌数据集验证这些结果。

结果

确定了 30 项研究,其中 16 项确定了与手术去瘤相关的蛋白表达,8 项确定了基因表达,1 项确定了 DNA 甲基化。个体化线性模型调整批次、分期和年龄后,仅发现 MTDH 和胰岛素样生长因子-1 受体(IGF1R)的表达与去瘤手术显著相关(P<0.05,假发现率(FDR)<5%),尽管在 IGF1R 的情况下,其与之前的发现方向相反。

结论

大多数研究受到设计的限制,包括异质样本,并且缺乏对主要混杂因素的调整。未来应常规收集高质量详细的临床注释,以更准确地评估手术结果的生物标志物。